Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Abstract

Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.

Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program

“…However, there was only one case of active TB observed in the LATAM group, and the EAER for active TB was < 0.1 E/100 PY. Although our results did not find an increased risk of TB reactivation in LATAM, TB screening is recommended before starting upadacitinib [ 8 , 9 , 12 – 17 ].…”

Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020)

“…Switching among biologic therapies is considered when the first course of treatment demonstrates insufficient efficacy or adverse effects, although patient and physician preference may also play a role 38 . Furthermore, studies show that up to 40% of patients do not respond to available treatments, including DMARDs 39 . Based on previous observations, switching was considered an alternate approach for controlling disease progression and severity 40 .…”

Use of biologic agents in rheumatoid arthritis: a bibliographic review

“…Segundo Bonfiglioli et al (2021) O MTX em monoterapia deve ser a primeira escolha terapêutica, na impossibilidade de uso do MTX, deve-se usar a LEF ou SSZ em monoterapia. Na segunda linha de tratamento, em caso de falha da monoterapia inicial (MTX, LEF, SSZ, HCQ/cloroquina), isto é, após 3 meses de tratamento, passa-se para troca de MMCDs ou a terapia com a combinação dupla ou tripla dos mesmos (MTX/LEF com HCQ/cloroquina ou MTX/ LEF com SSZ).…”